在现实世界队列中,在接受bempedoic酸治疗的患者中降低LDL-C
James Nelson1, LeAnne Bloedon2, Dave Lewandowski1
1Veradigm, Chicago, IL, USA.
Atherosclerosis plus
|February 27, 2026
概括
在患者中,佩多酸 (BA) 和BA与ezetimibe (BA+EZE) 显著降低了LDL-C. 不断使用和没有先前使用他类药物显示最大的LDL-C降低,突出治疗坚持的重要性.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 临床研究 临床研究
背景情况:
- 升高的低密度脂蛋白胆固醇 (LDL-C) 是心血管疾病的主要危险因素.
- 有限的现实世界数据存在于单独使用贝佩多酸 (BA) 或与以泽蒂米布 (BA+EZE) 结合的LDL-C降低.
研究的目的:
- 评估bempedoic acid (BA) 和bempedoic acid加ezetimibe (BA+EZE) 在降低LDL-C水平方面的实际有效性.
- 根据背景他类药物使用和持续治疗的坚持来评估LDL-C降低.
主要方法:
- 对患者开始BA或BA+EZE的电子健康记录和索赔数据的回顾性分析.
- 评估LDL-C水平在基线和开始后的3,6和12个月.
- 基于先前使用他类药物和持续治疗时间的患者分层.
主要成果:
- BA和BA+EZE都显示了3个月的显著中位数LDL-C降低 (分别为21%和33%).
- 达到LDL-C<70 mg/dL的患者比例显著增加了3个月,持续了12个月.
- 在使用持续治疗的患者和没有先前使用他类药物的患者中观察到更大的LDL-C降低.
结论:
- 贝佩多酸 (BA) 和BA+EZE提供早期和持续的降低LDL-C.
- 长期坚持治疗和不服用他类药物的患者的治疗对于最大限度地减少LDL-C至关重要.
- 这些发现支持使用BA和BA+EZE来治疗高脂血症.
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.6K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.6K
01:26Atherosclerosis III: Management
516
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
516
01:26Coronary Artery Disease IV: Preventive Measures
773
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
773
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
316
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
316
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
244
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
244
01:21Drug Dosing: Obese Patients
315
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
315